ReviewClinical and experimental medicine2025
Immunotherapy in EGFR-mutant non-small cell lung cancer.
Review in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Surgical and pathologic efficacy of neoadjuvant immunochemotherapy in EGFR-mutant non-small cell lung cancer.Translational lung cancer research · 2026Article
- Osteopontin Promotes Lung Cancer Growth through NF-κB-Dependent Upregulation of PD-L1 and Suppression of Anti-Tumor Immunity.Molecular biology reports · 2026Article
- Presenting features and outcomes to standard systemic therapies in patients with MTAP-deleted advanced non-small cell lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer.Future oncology (London, England) · 2026Review
- A Case of PrimaryCurrent oncology (Toronto, Ont.) · 2026Article
- Global trends and research progress on immunotherapy forJournal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR).For driver mutations, the use of EGFR tyrosine kinase inhibitors (TKIs) is the standard treatment, but acquired resistance is inevitable. There is currently no standard treatment for first-line TKI-resistant NSCLC patients. In recent years, although immune checkpoint inhibitors (ICIs) have transformed the treatment paradigm for advanced NSCLC without driver gene mutations, the clinical efficacy of these agents in patients with advanced NSCLC harboring EGFR mutations remains limited. Whether ICIs are suitable for patients with EGFR-mutated advanced NSCLC still warrants further investigation.This review summarizes several clinically utilized ICIs, presents clinical evidence regarding the efficacy of immunotherapy in patients with EGFR-mutated advanced NSCLC, and identifies EGFR-mutated subpopulations that may benefit from ICI treatment. On this basis, we explored more effective therapeutic strategies to extend the benefits of immunotherapy to a larger cohort of patients with EGFR-mutated NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.